Regentis Biomaterials is a privately held company focused on developing and commercializing proprietary hydrogels for tissue regeneration.
The Gelrin hydrogel platform is a matrix of polyethylene glycol diacrylate (PEG-DA) and denatured fibrinogen. This innovative hybrid technology combines the stability and versatility of a synthetic material with the bio-functionality of a natural substance for a range of clinical applications.
The company's flagship product, GelrinC©, is a ready-to-use hydrogel implant for the treatment of painful injuries to knee cartilage. GelrinC was issued CE Mark approval in 2013.